Thomas Struengmann

Thomas Strüngmann founded generic drug maker Hexal AG in 1986. In February he and his brother Andreas sold Hexal and their 67.7% of U.S. Eon Labs to Novartis for $7.5 billion.

• In 2005, Thomas Struengmann and twin Andreas sold their generic drug firm Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion.
• They cofounded Hexal in 1986. The company launched highly successful versions of the cholesterol-lowering drug simvastatin.
• The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.
• Their venture portfolio includes Germany’s BioNTech and Uruguay’s Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.
• In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.